<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 32 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page31.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=32">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 32 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 32</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=32"><img src="../thumb/32.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>Mims Medical Specialities

       Edited by: Dr JR Snyman MB ChB MPharm Med


                                     Warnings and special precautions:. Meas. baseline plasma   (S5) INJ. V/34/140, 141.
       1      CENTRAL NERVOUS        caff.conc.prior to init.treatm.in neonat. born to mothers consum.  779792-009: 0,5 mg/5 ml, 1x 5 ml amp, R368,61
                                                                  779806-018: 1 mg/10 ml, 1x 10 ml amp, R604,70
                                     large quant.of caff. prior to deliv., breast-feed.mothers to avoid caff.-
              SYSTEM                 contain.food/beverag./meds.as caff.excret.in breast milk, monit.base-  Dosage: IV use only.
                                     line plasma caff.conc.in newborns prev.treat.with theophylline prior
                                                                  Revers.gen.anaesth.adults: Init.: 0,2 mg (2 ml) IV over 15 sec., if
                                     to init. treatm., very premat.infts. (&lt; 28 wks.gestation.age &/or body   desir.respon.not obtain.within 45 sec.admin.2nd dos.of 0,2 mg (2 ml)
       1.1    Central nervous system   weight &lt;1000 g), newborns with seiz. disords./known CV dis./any   , rep.at 60 sec. interv.where necess.to max.total dose of 1 mg (10 ml).
                                     unusual rhythm disturbs. on CTG bef.birth, preterm neonates with
                                                                  Indiv.accord.pts.respons.with most pts. respond.to 0,6 mg-1 mg. In
              stimulants             imp. ren./hepat.funct., monit.pts.for developm.of necrotis. entero-  event of re-sedat. admin. repeat.dos.at 20 min.interv.as need. No
                                                                  more than 1 mg (given as 0,2 mg/min.) at one time & no more than
                                     colit., infts.suffer.gastro-oesophag. reflux, pregn & lactat., concom.
                                     meds known to interf. with caff.metabol., caffeine has a prolong. t½   3 mg in any hr. Admin.as series.of small inj.to allow.practit.good contr.
       1.1.1   Central analeptics    in premat.newborn infts.& potent.exists for accumulat., monit.plasma   Contraindications: Safety dur.pregn.& lact.not est., pts.receiv.ben-
                                                                  zodiazepin.for contr.of potent. life-threat.condits.
                                     conc.periodic.dur. treatm. in cases of incompl.clinic.respon./signs of
       Please note that Government Gazette No. 3390, Notice No. R32,   toxic., poss.generalis.incr.in metabol.result.in high. energy & nutrit.  Side effects: N&V, fatig., headache, inj.site pain/ reacts., cutan.
       1972, dated February 25th, 1972, proclaims that amphetamines be   requirem., diures.& electrol.loss induc. by CAYONA may necessit.cor-  vasodilat., agitat., dizzin., emot. lability, abnorm.vis.& hear., par-
       included in Part 1 of the Schedule to Act 41/1971 thus making them   rect.of fluid & electrol. disturbs., monit.card.rhythm & BP with concom.   aesthes., confus., convuls., somnol., speech disords., rigors, shiver.,
       PROHIBITED Dependence-producing Drugs. These products may   doxapram, rule out/treat.other caus.of apnoea prior to init.treatm.,   card.arrythm., bradycard., tachycard., hypertens., chest pain, hiccup.
       not be possessed, handled or kept by anybody, unless otherwise   fail.to respond to caff. treatm. may indicat.anoth. cause of apnoea.  Special precautions: Seiz.esp.in pts.suff.from epilep./ sev.hepat.
       authorised in terms of section 22a of Act 101 of 1965. Cognisance   Drug interactions: Caff.eliminat.poss.decr.with cimetidine & keto-  impairm.partic.aft.long-term treatm. with benzodiazepine/mix.drug
       should also be taken of Act 140 of 1992 as published in Government   conazole, caff.elimin.poss.incr. with phenobarb.& phenyt., incr.risk of   overdos., epilept. receiv.prolong.benzodiazepine treatm., in mix. drug
       Gazette No 14143 on 15 July 1992.  necrotis. enterocolit.with concom.meds.suppress.gastr.acid secret.   OD the toxic eff.of other drugs esp.cyclic antidepress. may emerge,
                                     (incl. H 2 recept.blocks./PPIs), potent. stimulat. effs.cardio-resp.syst.&   avoid rapid inject.in pts. with high dos.&/long term benzodiazepine
       PROVIGIL, Litha [N/P/S in C]  CNS with concom. doxapram    expos., withdr. sympts.habit.benzodiazepine users, provok. panic at-
       Modafinil.                                                 tack.in pts.with hist.thereof., monit. for re-sedat. resp.depress./oth-
       Indications: Improve wakefulness in pts.with excess. daytime   NALOXONE HCl FRESENIUS AMPS, Fresenius Kabi [P/S]  er resid. benzodiazep. eff. for up to 120 min., post-op.airway prob./
       sleepin.assoc.with narcolepsy as defin,by either of the two follow.  Naloxone HCl.  ventilatory insuffic.induc.by benzodiazepine not fully revers., precipit.
       DSM IV criteria in the absence of clinic.signific.medic./psychot.   Indications: Opioid induc.resp.depress., neonat. resp. depress.sec-  convuls./alter.blood flow.in head injur.pts rec.benzodiazepine, not
       condit. (1) Dly.recur.daytime naps/lapses into sleep x3mnths plus   ond.to opioid admin.to mother.  recomm.for benzodiazepine depend.treatm./managem.of protract.
       sudd.bilat.loss of postur. musc. tone in assoc.with intense emot. (2)   (S4) INJ. 27/1.4/0157, 27/1.4/0158.  benzodiazepine abstin.syndr.
       excess.sleepin./ sudd. musc.weakn.with assoc. features.e.g. sleep   701982-003: 0,02 mg/ml, 10x2 ml amps, R242,43  Drug interactions: Blocks central effs.of benzodiazepines by com-
       paralysis, automat. behaviours,disrupt.maj.sleep episod., polysom-  702097-003: 0,4 mg/ml, 10x1 ml amps, R237,36  petit.interact at receptor lev., eff.of non-benzodiazepine agon.at ben-
       nography demonstrat.sleep latency of less than 10 mins or rapid eye   Dosage: Admin.SC, IM/IV. IV admin.recomm.in emerg. Adults:   zodiazepine recept.are block.
       movem sleep latency less than 20 mins.  Opioid toxic: 0,4-2 mg IV at 2-3 min. interv.as need. If no response
       (S5) TABS. 37/1.1/0025        aft.tot.dos. of 10 mg cons. diagn.of OD from other agents.  CONCERTA, Janssen Pharmaceutica [N/P/S in C] &
       701388-001: 100 mg, 30, R1 135,60  Post-op opioid depress: 0,1-0,2 mg IV at interv.of at least 2 mins.  Methylphenidate HCl.
       Dosage: Adults: 200 mg/day giv.as sngl.morn. dos.  to obtain an optimum resp.response while maintain.adeq.analges.  Indications: Attent.deficit hyperactiv.disord.in childr.& adolesc.(6-17
       Contraindications: Maj.anx.outside specialis. units, childr.& ado-  Paediatr:  yrs) & adults (18-65 yrs) meet.DSM-IV criteria.
       lesc.und.16 yrs., sev.ren. impairm., safety in pregn.& lactat.not est.,   Neonat.opioid induc.depress: 0,01 mg/kg bm IM, IV or SC, rep.  (S6) ER TABS. 37/1.2/0322, 42/1.2/0282, 37/1.2/0323, 0324
       hist.of left ventric.hypertrophpy/ischaem.ECG changes, chest pain,   at 2-3 min.interv.if necess. Alternat. sngl.IM of 0,06 mg/kg bm at   704161-001: 18 mg, 30, R735,67
       arrhythm., other clinic.signific. manifestat. of mitral valve prolapse.  birth for a prolong.act.  714559-001: 27 mg, 30, R743,55
       Side effects: Headache, infect., GI disturbs., CNS effs., chest & neck   Opioid toxic: Childr: 0,01 mg/kg bm IV follow.by 0,1 mg/kg bm if necess.  704162-001: 36 mg, 30, R809,20
       pain, rhinit., pharyngit., lung disords., dyspn., trans.ischaem.T-wave   Side effects: N&V, hypertens., card.arrhythm., hypotens., pulmon.oed., seiz.  704163-001: 54 mg, 30, R931,81
       changes in assoc. with mitral valve prolapse/left ventric. hypertrophy,   Special precautions: Act.of some opioids may exceed naloxone   Dosage: Admin.once dly in morn. Eff. shown to be pres.12 hrs.aft.
       gen.oed., asthma, epistax., hypo/ hypertens., vasodilat., arrhythm., syn-  HCl & rep.dos.may be reqd., monit. pt.contin., poss.precipitat.of   dos. Swallow whole without crush/ div./chew. Indiv.
       cope, hyperglycaem., joint disords., H Simplex, dry skin, urin.retent., ab-  ac.withdr. syndr. in opioid depend.pts.or neonates of such mothers.  New pts/ pts.taking other stimul: Childr.& adolesc: 18 mg once
       norm.urine & ejaculat., allerg. reacts., personality disords., abuse potent.  dly. Adults: 18 or 36 mg once dly.
       Special precautions: Elderly, hepat.fail., incr. pregn. risk with ster-  PHARMA-Q NALOXONE HCl INJECTION 0,4 mg/ml,   Tfd.of pts.currently using methylphenidate: Use clinic.judgem.
       oid.contracept.& for 1 mnth. aft. discont.ther.theref.alt.contracept.  Pharma-Q [P/S]  18 mg once dly.for pts. tak.5 mg methylphenidate 2-3xdly., 36 mg
       recomm., specialist monit.necess., monit.BP and heart rate in hy-  Naloxone HCl.  once dly.for pts. tak. 10 mg methylphenidate 2-3xdly., 54 mg once
       pertens. pts., recent MI hist., unstable angina, psychosis hist., avoid   Indications: Revers.of opioid centr.depress. incl.resp.depress.induc.  dly. for pts.tak.15 mg methylphenidate 2-3xdly., 72 mg once dly.for
       alcohol, concom. TCA’s & anticonvuls., monit.prothromb.times with   by natur./synth. opioids dur.known/suspect.opioid overdos./post-op   pts.tak.20 mg methylphenidate 2-3xdly.
       concom. warfar., monit.for phenytoin toxic.with concom. phenytoin,   foll.opioid use dur.surg./neonat.resp.depress. second.to opioid ad-  Dos.adjustm: Adjust in 18 mg increm.at approx. wkly. interv.
       concom.MAOI/CNS act.drugs & cardiovasc. drugs as interact.stud-  min. to mother dur.labour.  Childr.6-12 yrs: up to max.54 mg/ day. Adolesc: 13-18 yrs: up to
       ies not perform., hist.of drug &/stimul.abuse.  (S4) INJ. 34/1.4/0165. 0,4 mg/ml  max.72 mg/day. Adults: up to max.108 mg/ day. Dos.above indiv.
       Drug interactions: Eff.of OC’s poss.impair., interacts. with drugs   704187-001: 10x1 ml amps, R216,33  max.dly. dos.not recomm.
       that inhib./ induc/metabol.by cytochrome P-450 isoenzymes and   Dosage: Admin.SC, IM/IV. IV admin.usual.for rapid onset & recomm.  Contraindications: Mark.anx./tens./agitat., glauc., Tourette’s syndr./
       other hepat. enzymes.         in emerg. Do not mix with bisulph. contain.preps./long-chain or high   family hist.thereof, MAOI, hyperthyroid., card.dysrhythm., ischaem.
                                     molec. weight anions/alkaline pH sols.  heart dis., uncontr. hypertens., pregn.& lactat.
                                     Opioid overdos: Adults: 0,4-2 mg IV at 2-3 min. interv.as need. Con-  Side effects: Heart rate/BP chang., sudd.death report.in pts.with struct.
       1.1.2   Respiratory stimulants  sid. diagn.of OD from other agents if no response aft.tot.dos. of 10 mg.  card.abnormalit., nasopharyngit., URTI, sinusit., bld.dyscras., decr. ap-
                                                                  pet., anorex., reduc.weight/height gain in childr. on prolong.ther., in-
                                     Childr: Usual init.dos: 10 µg/kg bm IV follow.by larg.dos.of 100 µg/
                                     kg bm if necess.             somn., nervousn., affect labilit., agitat., aggress., anx., depress., irritabil.,
       CAYONA, Safeline [P/S]        Post-op opioid depress: Adults: 0,1-0,2 mg IV at interv.of at least   mood swings, abnorm.behav., tics, libido disord., tens., bruxism, panic
       Caffeine citr.equiv.to caffeine  2 mins.to obtain an optim. resp. response while maint.adeq.analges.  attack, psychot.disords., anger, suic.ideat./attempt, restlessn., tear-
       Indications: Prim. apnoea of prem. Newborns  Neonates: 0,01 mg/kg bm IM, IV or SC, rep.at 2-3 min.interv.if necess.   fuln., pre-exist. Tourette’s syndr.tics worsen., hypervigil., sleep disord.,
       (S3) SOL.FOR INFS.& ORAL SOL, 48/1.4/0091  Alternat. sngl.IM dos.of 0,06 mg/kg bm at birth for a more prolong.act.  apathy, repet.behav., over-focuss., delus., thought disturbs., depend.&
       720951-002: 20 mg/ml, 10 amps, R3 807,28  Sustain.opoid antagon: IV infus.at conc.of 4 µg/ml in NaCl   abuse, headache, dizzin., psychomot. hyperactiv., somnol., paraesthes.,
       Dosage: Admin.by IV infus.by syringe infus. pump/ other met.infus.  0,9%/5% dextr.infus.at a rate titr.accord.to pt.respons., both to in-  sedat., tremor, lethargy, choreo-athetoid movem., revers. ischaem.neu-
       device &/ oral route, init. und. supervis.of physic.experienc.in neo-  fus.& prev. bolus inj.  rolog.defic., NMS, CV/accomodat.disords., migraine, diplop., mydrias.,
       nat.intens. care., Admin.only in neonat.ICU with adeq.facilit. avail.   Contraindications: Safety dur.pregn.& lactat. not est.  vis.impairm., vertigo, arrhythm., tachycard., palpit., chest pain/discomf.,
       for pt.surveil./monitor., do not mix./admin. concom. with other meds.  Side effects: N&V, hypertens., card.arrhythm., pulm. oed., seiz.  card. arrest, MI, hypertens., cerebr.arterit.&/occlus., periph. coldn., hot
       Prev.untreat.infts.: Load.dos.: 20 mg/kg/body weight admin.by   flush, cough, oropharyng.pain, dyspn., GI disturbs., hepat.enzym.ele-
       slow IV infus.over 30 min. Maint. dos.(begin.24 hrs.aft.load.dos):   Special precautions: Act. of some opioids may exceed naloxone HCl   vat., abnorm. liv. funct.incl.hepat.coma, hepatocellul.injury, ac. hepat.
                                     & rep.dos.may be reqd., contin. pt.monit.necess.to detect.re-emerg.of
       5 mg/kg body weight IV (over 10 mins.)/by oral admin.every 24 hrs  fail., skin reacts. incl.macul.rash/bullous condits./erythem. multiforme/
       In preterm infts.with insuffic.clin.response to recomm. load.dos.a   opioid toxic.foll.init.revers., ac.withdr.syndr. poss. precipit.where large   exfolat.dermatit./ prurit.& exanthem. NEC, hyperhidros., angioneurot.
       second load.dos.of max.10-20 mg/kg may be giv.aft.24 hrs., a high.  opioid dos.recd./in physic. opioid depend.or neonates of such mothers.  oed., musc.tightn./spasm/cramps/twitch., haematur., pollakur., erect.
       maint.dos. of 10 mg/kg body weight could be consid.in case of insuffic.  dysfunct., gynaecomast., pyrex., fatig., thirst, asthen., card. murmur, decr.
       resp. Discont.admin.when pt.has 5-7 days without a signific.apnoeic   weight, hypersens. incl.anaphylact. reacts., auricul.swell., hallucinat.,
       attack. Reconsid. diagnos. of apnoea of premat.if respons.not adeq.   1.1.3  Others  mania., logorrh., libido disord., convuls., cerebr.vasculit./-haemorrh/
       to 2  load.dos./maint.of 10 mg/kg/day.
         nd
       Pts.with recurr.apnoea: Restart.with eith. maint. dos./half a load.  CONCERTA (MDR Listing)  -arterit./-occlus., dyskines., ang. pect., bradycard., supraventr.tachy-
                                                                  card., ventr.extrasyst., Raynauds., alopec., arthralg., myalg., priapism,
       dos.depend.on time interv. from discont.to recurr.of apnoea.  NEUCON (MDR Listing)
       Contraindications: IM/SC/intrathec./ intraperiton. inj., con-  decr.ther. respons./drug eff., hyperpyrex.
                                                                  Warnings and special precautions: Underly. med.condits.poss.
       com theophyll.                ANEXATE, Pharmaco [P/S]
       Side effects: CNS stimulat.incl. irritabil./ restlessn./ jitterin, card.  Flumazenil.  compromis.by incr. heart rate/ BP, monit.hypertens.pts., struct. card.
       effs.incl.tachycard./ hypertens./ incr.stroke vol., seps., hypersens. re-  Indications: Revers.of benzodiazepines sedat. eff.where gen.  abnormalit. where sudd.death report., lact.intol., not for use in childr.
       act., brain inj., convuls., deafn, regurgitat., incr. gastr. aspir., necrotis.  anaesth.induc.& /maintain with benzodiazepines, where sedat.pro-  und.6 yrs.as insuffic.data avail.on safety of long-term use, prior clinic.
       enterocolit., infus.site phlebit./ inflammat., incr.urine output/urine Na/   duc.with benzodiazepines for diagnost.& therapeut.proced., man-  eval.for fam.hist.of tics., growth retardat.in childr.theref.monit.dur. pro-
       urine Ca, decr.Hb/thyrox.     agem.of benzodiazepines overdos.  long. ther., monit.long-term treatm.interupt.treatm.of pts. not grow./</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page31.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page27.html">27</a>&nbsp;&nbsp;&nbsp;<a href="page28.html">28</a>&nbsp;&nbsp;&nbsp;<a href="page29.html">29</a>&nbsp;&nbsp;&nbsp;<a href="page30.html">30</a>&nbsp;&nbsp;&nbsp;<a href="page31.html">31</a>&nbsp;&nbsp;&nbsp;<a href="page32.html">32</a>&nbsp;&nbsp;&nbsp;<a href="page33.html">33</a>&nbsp;&nbsp;&nbsp;<a href="page34.html">34</a>&nbsp;&nbsp;&nbsp;<a href="page35.html">35</a>&nbsp;&nbsp;&nbsp;<a href="page36.html">36</a>&nbsp;&nbsp;&nbsp;<a href="page37.html">37</a>
             </td>
             <td width="35%"><a href="page33.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page33.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
